Ketamine Assisted Psychotherapy (KAP)-Experiential Training for Providers

Ketamine Assisted Psychotherapy (KAP)-Experiential Training for ProvidersCompelling evidence has been published across the country from leading universities such as Johns Hopkins on the use of psychedelic medicines such as psilocybin, MDMA, and ketamine to treat mental health conditions that do not respond to traditional pharmaceuticals. Ketamine is the first legal psychedelic medicine that is available to the U.S. public. In 2019, the FDA approved an intranasal formulation of ketamine, Spravato, which received breakthrough designation from the FDA. Ketamine is being hailed as the most significant development in psychiatry since the advent of SSRIs and has been shown consistently in the research to rapidly reverse suicidality. Ketamine is an effective treatment for various mental health conditions including: major depression, anxiety, PTSD, OCD, and bipolar disorder.

The efficacy of ketamine is significantly enhanced when combined with psychotherapy. Ketamine Assisted Psychotherapy or (KAP) utilizes the key principles of proper screening, preparation, set, setting, preparation, dosage, and integration to optimize safety/efficacy.

We believe the best way to learn and properly facilitate this modality to patients is to first experience it yourself; there is no replacement for direct experience.

To meet the demand in the Seattle area for training on this effective modality, AIMS institute is offering a 10-hr certificate in experiential KAP training specifically tailored for licensed providers.

Training Outline:

  • Screening/Preparation (1-2 hours)
  • Intro/Fundamentals of KAP (Online Materials, Readings, 4.25 hours)
  • Guided Experiential Session (3-hours)
  • Integration (0.75 hours)

Cost of Training:

If you are on one of our accepted insurance plans (listed on our website aimsinstitute.net), your insurance plan is utilized for screening, preparation, and integration visits. The experiential ketamine and didactic training/recorded online materials and mindfold are not covered by insurance and is an out of pocket fee of $960 (+ tax for educational materials). If you are not on one of our accepted insurance plans, then out of pocket prices for screening, preparation, and integration would be applied. To apply email info@aimsinstitute.net or call (206) 420-1321.

Curriculum Developer:

Nathaniel Schmidt DNP, ARNP, PMHNP-BC is a psychiatric nurse practitioner who has worked in critical care, inpatient psychiatry, community mental health, and addiction. He completed his undergraduate degree at the University of Oklahoma and doctorate at the University of Washington. He is a graduate of the MAPS MDMA provider training program and has been a speaker with KRIYA Institute and the UW School of Nursing. He has been a featured speaker on Tangentially Speaking hosted by NY Times best-selling author Christopher Ryan and The Myths That Make Us hosted by Erick Godsey. He was a provider with AIMS Institute providing ketamine-assisted psychotherapy from 2018-2020.

Download Training Provider Flyer

Latest Blog Posts

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care 

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care 

Healthcare Disparities in African American Communities African Americans continue to face significant disparities in healthcare. From higher mortality rates for chronic conditions like cancer and heart disease to underdiagnosis of autoimmune disorders, these inequities stem from systemic racism, implicit bias, and a lack of cultural sensitivity among providers. Studies show that Black patients are less likely to receive adequate pain management and more likely to feel unheard or dismissed during medical visits. These disparities erode trust in the healthcare system and lead to poorer outcomes and avoidable suffering. For many, navigating the system can feel isolating and disempowering, leaving them ...

Read More
At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

A recent paper in the Frontiers in Medicine states that An underutilized intervention for long  COVID is low dose naltrexone, which has an established safety profile for a variety of conditions. ‘Naltrexone is a non-selective opioid antagonist currently approved by the US Food and Drug Administration (FDA) for the treatment of alcohol and opioid dependence and is prescribed at 50–150 mg daily. At doses below 5 mg, it is considered low-dose naltrexone (LDN), exhibits anti-inflammatory and analgesic properties, and has been used off-label to reduce severity of symptoms in conditions such as fibromyalgia, multiple sclerosis, complex regional pain syndrome, myalgic encephalomyelitis/chronic fatigue ...

Read More
Unusual Suspects

Unusual Suspects

Psychedelic Therapies Gain New Advocates Texas Law Magazine Written by Robin Berghaus. Art by Matthieu Bourel Published November 6, 2024 Marcus Capone served seven combat tours as a Navy SEAL — including missions with SEAL Team Six, the nation’s preeminent counterterrorism unit — before being medically retired in 2013. For years, he struggled to find effective treatments for his traumatic brain injuries, depression, and post-traumatic stress disorder. Capone tried antidepressants, talk therapy, hyperbaric oxygen therapy, transcranial magnetic stimulation, and he visited several brain clinics. Nothing worked. When Capone’s life began falling apart, he considered suicide. His wife was just as ...

Read More
Call Us Text Us
Skip to content